The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Capecitabine
Related studies linked through entity extraction aliases.
Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
- Status
- RECRUITING
- Phase
- PHASE3
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
- Status
- TERMINATED
- Phase
- PHASE2
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study on Androgen Receptor and Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study
- Status
- UNKNOWN
- Phase
- PHASE2
Two Chemotherapy Regimens Plus or Minus Bevacizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
- Status
- UNKNOWN
- Phase
- PHASE2
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
- Status
- TERMINATED
- Phase
- PHASE3
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
- Status
- TERMINATED
- Phase
- PHASE2
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
- Status
- TERMINATED
- Phase
- PHASE3